Richmond biotech BrainBox Solutions Inc., the maker of an artificial intelligence-enabled concussion test, has earned a broad patent from the U.S. Patent and Trademark Office for a set of eight biomarkers that correlate to specific findings on MRI tests.
CEO Donna Edmonds said in a statement the biomarkers covered by the patent include indicators of specific brain dysfunction, “enabling objective assessments of longer-term injury risk and the need for further monitoring and diagnostic testing.”
The patent also provides a foundation for future application in the diagnosis and monitoring of neurologic disease, Edmunds said.
Its product incorporates a panel of its patented blood biomarkers as well as neurocognitive testing to provide a single–system score that measures the severity of a brain injury and post-concussive symptoms.
The company said its lead traumatic brain injury test for adults is in the final enrollment phase for a clinical trial that could lead to bringing the…
Read the full story from the Washington Business Journal.
